Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3560395 | 1.00 | AR (0.52) | ARTRPV4 | |
| SCHEMBL4596989 | 1.00 | AR (0.52) | ARTRPV4 | |
| SCHEMBL23134696 | 1.00 | AR (0.52) | ARTRPV4 | |
| SCHEMBL30588443 | 1.00 | AR (0.52) | ARTRPV4 | |
| SCHEMBL4597254 | 0.88 | AR (0.38) | AR | |
| SCHEMBL3568982 | 0.88 | AR (0.38) | AR | |
| SCHEMBL4597253 | 0.88 | AR (0.38) | AR | |
| SCHEMBL6859327 | 0.85 | AR (0.36) | AR | |
| SCHEMBL6859331 | 0.85 | AR (0.36) | AR | |
| SCHEMBL13269795 | 0.85 | AR (0.36) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040010037-A1 | Cyanophenyl derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. | 2004-01-15 | — | — | US | claimed |
| CN-114761003-B | Novel ureas having androgen receptor degrading activity and uses thereof | 冰洲石生物科技公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20230150973-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-11420956-B2 | Ureas having Androgen Receptor degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2022-08-23 | — | — | US | disclosed |
| CN-114761003-A | Novel ureas having androgen receptor degrading activity and use thereof | 冰洲石生物科技公司 | 2022-07-15 | — | — | CN | disclosed |
| US-11220490-B2 | Ureas having androgen receptor degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2022-01-11 | — | — | US | disclosed |
| US-20210300901-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2021-09-30 | — | — | US | disclosed |
| US-20210087170-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2021-03-25 | — | — | US | disclosed |
| EP-1122242-B1 | CYANOPHENYL DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2008-01-16 | — | — | EP | disclosed |
| US-20040010037-A1 | Cyanophenyl derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. | 2004-01-15 | — | — | US | disclosed |
| US-6673799-B1 | INHIBITS BINDING TO ANDROGEN RECEPTOR; ANTIANDROGEN | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-01-06 | — | — | US | disclosed |
| EP-1122242-A1 | CYANOPHENYL DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2001-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11420956-B2 | Ureas having Androgen Receptor degradation activity and uses thereof | AR, UTS2R, ESRRA | AR 1/4885TRPV4 3866/4885 |
| US-20040010037-A1 | Cyanophenyl derivative | BPHL, AR, KLK3 | AR 2/4885TRPV4 2659/4885 |
| US-20210300901-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | AR, UTS2R, ESRRA | AR 1/4885TRPV4 3927/4885 |
| US-11220490-B2 | Ureas having androgen receptor degradation activity and uses thereof | AR, UTS2R, ESRRA | AR 1/4885TRPV4 3866/4885 |
| US-20210087170-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | AR, UTS2R, ESRRA | AR 1/4885TRPV4 3927/4885 |
| US-20230150973-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | AR, UTS2R, ESRRA | AR 1/4885TRPV4 3927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.